Velvio
Private Company
Funding information not available
Overview
Velvio is a preclinical-stage biotech targeting a central biological pathway, TGF-β signaling, with a proprietary LNA-gapmer antisense oligonucleotide platform. Its lead candidate, NVP-13, is designed to downregulate TGFBR2 synthesis to revert inflammation, fibrosis, and restore tissue repair, with first-in-human studies imminent in ALS. The company is pursuing high-unmet-need indications in neurodegeneration, pulmonary fibrosis, and oncology, positioning its platform technology for broad therapeutic application. Led by a small team of experienced founders, Velvio is advancing towards clinical proof-of-concept.
Technology Platform
Proprietary Locked Nucleic Acid (LNA) gapmer antisense oligonucleotide (ASO) platform designed for gymnotic cellular uptake and targeting of TGFBR2 mRNA to downregulate pathological TGF-β signaling.
Opportunities
Risk Factors
Competitive Landscape
In ALS, Velvio competes with other ASO developers (e.g., Ionis, Biogen) and novel mechanism approaches. In IPF, it faces established anti-fibrotics and numerous clinical-stage biologics. In TGF-β oncology, it competes with large pharma (e.g., Merck's bintrafusp alfa program) and other modality approaches. Velvio's differentiation lies in its specific mRNA-targeting ASO approach to TGFBR2.